Welcome to our dedicated page for Vertex Pharmaceuticals SEC filings (Ticker: VRTX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Vertex Pharmaceuticals filings document the biotechnology company’s operating results, governance and product-development disclosures. Recent Form 8-K reports include quarterly and annual results releases, selected regulatory and pipeline events involving therapies such as povetacicept, and officer or director transition disclosures.
The company’s proxy materials cover board composition, director nominees, shareholder meeting matters, executive compensation and equity-award information. Vertex filings also provide formal records for disclosure topics tied to its approved medicines, clinical pipeline and governance structure as a Nasdaq-listed operating company.
Carmen R. Bozic reported multiple open-market dispositions of Common Stock under a Form 144 notice. The filing lists five sales on 03/13/2026, 03/27/2026, 05/12/2026, 05/15/2026, and 05/29/2026 with reported share counts of 2,329, 2,329, 6,988, 1,354, and 1,974 respectively and the corresponding consideration amounts shown in the filing.
The notice also lists Fidelity Brokerage Services LLC as the brokerage location and records an entry for Restricted Stock Vesting dated 02/10/2026.
Vertex Pharmaceuticals executive Joy Liu reported an open-market sale of company stock. As EVP and Chief Legal Officer, she sold 828 shares of Common Stock at a price of $439.91 per share on June 1, 2026. After this transaction, she directly holds 19,959 shares of Vertex common stock. The sale was made under a pre-arranged company-approved trading plan established pursuant to Rule 10b5-1, indicating it was scheduled in advance rather than timed discretionarily.
Vertex Pharmaceuticals executive Carmen Bozic reported an open-market sale of 1,974 shares of Common Stock at $450.00 per share. The transaction left her with 22,760 shares held directly. According to the disclosure, the sale was made under a pre-arranged Rule 10b5-1 trading plan entered into on 11/20/2025, indicating it was scheduled in advance rather than timed discretionarily.
Vertex Pharmaceuticals insider sale notice: A Form 144 submission lists proposed or recent dispositions of Common stock by Joy Liu. The excerpt shows three reported sales in the past three months: 03/02/2026 (892 shares, $442,396.32), 04/01/2026 (978 shares, $439,288.26), and 05/01/2026 (1,104 shares, $469,222.08). The filing also records an allocation of 828 shares tied to Restricted Stock Vesting dated 02/26/2025.
VRTX reported proposed sales and recent dispositions in a Form 144 submission. The filing lists two restricted stock vesting events (1,020 shares on 02/17/2026 and 954 shares on 02/24/2026) and four reported sales by Carmen R. Bozic between 03/13/2026 and 05/15/2026.
Vertex Pharmaceuticals executive Mark E. Bunnage reported a small open-market sale of company stock. On this Form 4, the EVP and Chief Scientific Officer sold 33 shares of Common Stock at $453.45 per share and now directly holds 7,284 shares. The transaction was made under a pre-arranged Rule 10b5-1 trading plan entered into on November 26, 2025.
Vertex Pharmaceuticals EVP and CMO Dr. Carmen Bozic sold 1,354 shares of Common Stock in an open-market transaction on May 15, 2026 at an average price of $453.45 per share. After this sale, she directly holds 24,734 shares. The trade was made under a pre-arranged Rule 10b5-1 company-approved trading plan entered into on November 20, 2025.
Vertex Pharmaceuticals submitted a Form 144 notice reporting proposed sales of Common Stock by an insider. The filing lists multiple past transactions in the prior three months and a proposed sale routed through Fidelity Brokerage Services LLC on 05/15/2026. The sales are linked to restricted stock vesting and compensation.
VRTX filing reports insider sale notices and a small employee share purchase. Mark Bunnage sold 2,437 shares on 02/17/2026 for $1,192,814.02, 1,182 shares on 02/18/2026 for $559,889.76, and 620 shares on 02/25/2026 for $301,537.00. The filing also lists a 33-share ESPP purchase on 05/14/2026.
Vertex Pharmaceuticals EVP and CMO Carmen Bozic reported an open-market sale of 6,988 shares of Common Stock at $450.00 per share. After this transaction, she directly holds 26,088 shares. The sale was carried out under a company-approved Rule 10b5-1 trading plan entered into on 11/20/2025.